期刊文献+

雄激素阻断治疗后前列腺癌组织中肿瘤干细胞比例变化 被引量:3

Androgen Deprivation Therapy Can Change Proportion of Prostate Cancer Stem Cells
下载PDF
导出
摘要 目的研究雄激素阻断治疗(androgen deprivation therapy,ADT)对前列腺癌组织中肿瘤干细胞比例的影响,探讨激素非依赖性前列腺癌形成的机制。方法实验分为ADT治疗组和无ADT治疗组,应用免疫荧光技术比较两组前列腺癌患者术前术后标本中肿瘤干细胞的比例变化。结果无ADT组术前穿刺标本和前列腺根治切除术后标本肿瘤干细胞比例差异无统计学意义[(3.56±1.33)%vs.(3.78±1.39)%,n=9,t=-0.686,P=0.512],在ADT组,接受雄激素阻断治疗3月后,与穿刺标本比较,根治切除标本中前列腺癌肿瘤干细胞比例明显升高[(3.44±1.81)%vs.(9.22±1.71)%,n=9,t=-6.353,P=0.000]。在癌旁组织,也可见ADT后干细胞标志的增加。结论雄激素可能参与前列腺和前列腺癌组织中干细胞的分化;雄激素非依赖性前列腺癌的形成可能与前列腺癌肿瘤干细胞有关。 Objective To study the effect of androgen deprivation therapy on prostate cancer stem cells in prostate cancer tissues and to investigate the mechanisms of the formation of androgen independent prostate cancer. Methods Eighteen patients were divided into 2 groups, the ADT(androgen deprivation therapy) group and non-ADT group. The proportions of cancer stem cells in preoperative and postoperative prostate cancer tissues were compared with immunofl uorescence. Results In the non-ADT group, the differences of cancer stem cell proportion between preoperative and postoperative specimens were not prominent[(3.56 ±1.33)% vs.(3.78±1.39)%,n = 9, t =-0.686, P = 0.512]. But in the ADT group, compared with preoperative specimens, the proportion of prostate cancer stem cells was signifi cantly increased after undergoing androgen deprivation therapy for 3 months [(3.44±1.81)% vs.(9.22±1.71)%,n = 9, t =-6.353, P = 0.000]. In the tissue adjacent to carcinoma, stem cell markers were also increased after ADT. Conclusion Androgen probably is involved in the differentiation of prostate stem cells or prostate cancer stem cells. The formation of androgen independent prostate cancer may be related to prostate cancer stem cells.
作者 陈伟 王国民
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2014年第2期128-130,共3页 Cancer Research on Prevention and Treatment
基金 教育部博士点专项基金资助项目(20090071120024)
关键词 肿瘤干细胞 雄激素非依赖性前列腺癌 雄激素阻断治疗 Cancer stem cells Androgen independent prostate cancer Androgen deprivation therapy
  • 相关文献

参考文献15

  • 1Labrie F,Dupont A,Cusan L. Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer:7-year clinical experience[J].{H}Journal of Steroid Biochemistry,1990,(06):943-950.
  • 2Huggins C,Hodges CV. Studies on prostatic cancer:I.The effect of castration,of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate.1941[J].{H}Journal Of Urology,2002,(01):9-12.
  • 3Macfarlane R J,Chi KN. Research in castration-resistant prostate cancer:what does the future hold[J].Curr Oncol,2010,(Suppl 2):S80-S86.
  • 4Scher HI,Halabi S,Tannock I. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:recommendations of the prostate cancer clinical trials working group[J].{H}Journal of Clinical Oncology,2008,(07):1148-1159.
  • 5Heidenreich A,Aus G,Bolla M. EAU guidelines on prostate cancer[J].{H}EUROPEAN UROLOGY,2008,(01):68-80.
  • 6Pajonk F,Vlashi E,McBride WH. Radiation resistance of cancer stem cells:the 4 R's of radiobiology revisited[J].{H}STEM CELLS,2010,(04):639-648.
  • 7Silvestre DC,Pineda JR,Hoffschir F. Alternative lengthening of telomeres in human glioma stem cells[J].{H}STEM CELLS,2011,(03):440-451.
  • 8Taipale J,Beachy PA. The Hedgehog and Wnt signalling pathways in cancer[J].{H}NATURE,2001,(6835):349-354.
  • 9Rizzo S,Hersey JM,Mellor P. Ovarian cancer stem celllike side populations are enriched following chemotherapyy and overexpress EZH2[J].{H}Molecular Cancer Therapautics,2011,(02):325-335.
  • 10Wei J,Barr J,Kong LY. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway[J].{H}Molecular Cancer Therapautics,2010,(01):67-78.

同被引文献25

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部